|
44 Companies |
|
44 Products |
|
44 Products |
|
19 Mechanisms of Action |
|
0 Trials |
|
104 News |
|
| 123» |
- | dexamethasone / Generic mfg.
Enrollment change: A Phase I/IIa Study for the Treatment of Uveitis With Iontophoresis (clinicaltrials.gov) - May 30, 2024
P1/2, N=0, Withdrawn, Sponsor: Asociaci
N=30 --> 0
- | Avastin (bevacizumab) / Roche
Trial withdrawal: Intravitreal Bevacizumab for Inflammatory Neovascular Membranes (clinicaltrials.gov) - May 29, 2024
P3, N=0, Withdrawn, Sponsor: Asociaci
N=30 --> 0 Completed --> Withdrawn
- | Orencia (abatacept) / BMS
Trial completion: Abatacept in the Treatment of Uveitis (clinicaltrials.gov) - Aug 21, 2018
P2, N=10, Completed, Sponsor: Oregon Health and Science University
Completed --> Withdrawn Active, not recruiting --> Completed
- | cyclosporin A microemulsion / Generic mfg.
Trial completion, Enrollment change: Interferon-alpha2a Versus Cyclosporin A for Severe Ocular Behcet's Disease (INCYTOB) (clinicaltrials.gov) - Jun 2, 2018
P3, N=37, Completed, Sponsor: University Hospital Tuebingen
Active, not recruiting --> Completed Recruiting --> Completed | N=100 --> 37
- | Enrollment change, Trial withdrawal: Grading Scale of Vitreous Haze in Patients With Uveitis Using Ultrasonography (clinicaltrials.gov) - Apr 11, 2018
P=N/A, N=0, Withdrawn, Sponsor: University of Nebraska
Recruiting --> Completed | N=100 --> 37 N=170 --> 0 | Not yet recruiting --> Withdrawn
- piclidenoson (CF101) - Can / Fite
Enrollment change, Trial withdrawal: Safety &Efficacy of CF101 to Subjects With Uveitis (clinicaltrials.gov) - Feb 1, 2018
P2, N=0, Withdrawn, Sponsor: Can-Fite BioPharma
N=170 --> 0 | Not yet recruiting --> Withdrawn N=45 --> 0 | Not yet recruiting --> Withdrawn
- | piclidenoson (CF101) - Can / Fite
Trial initiation date, Trial primary completion date: Safety &Efficacy of CF101 to Subjects With Uveitis (clinicaltrials.gov) - Jan 25, 2018
P2, N=45, Not yet recruiting, Sponsor: Can-Fite BioPharma
N=45 --> 0 | Not yet recruiting --> Withdrawn Initiation date: Jan 2017 --> Jan 2019 | Trial primary completion date: Sep 2018 --> Sep 2019
- | NN1213 / Novo Nordisk
Trial completion, Immune cell: Immune Indicators of Uveitis (clinicaltrials.gov) - Jun 30, 2017
P=N/A, N=100, Completed, Sponsor: National Eye Institute (NEI)
Initiation date: Jan 2017 --> Jan 2019 | Trial primary completion date: Sep 2018 --> Sep 2019 Recruiting --> Completed
- | Zinbryta (daclizumab) / Biogen, AbbVie
Trial completion: Daclizumab and Sirolimus to Treat Uveitis (clinicaltrials.gov) - Jun 30, 2017
P1, N=6, Completed, Sponsor: National Eye Institute (NEI)
Recruiting --> Completed Active, not recruiting --> Completed
- | Zinbryta (daclizumab) / Biogen, AbbVie
Trial completion: Daclizumab to Treat Non-Infectious Sight-Threatening Uveitis (clinicaltrials.gov) - Jun 30, 2017
P2, N=6, Completed, Sponsor: National Eye Institute (NEI)
Active, not recruiting --> Completed No longer recruiting --> Completed
- | NN1213 / Novo Nordisk
Trial completion: Evaluation and Treatment of Patients With Inflammatory Eye Diseases (clinicaltrials.gov) - Jun 30, 2017
P=N/A, N=300, Completed, Sponsor: National Eye Institute (NEI)
No longer recruiting --> Completed Recruiting --> Completed
- | NN1213 / Novo Nordisk, Zinbryta (daclizumab) / Biogen, AbbVie
Trial completion: ANTI-TAC THERAPY FOR UVEITIS (clinicaltrials.gov) - Jun 30, 2017
P1, N=15, Completed, Sponsor: National Eye Institute (NEI)
Recruiting --> Completed No longer recruiting --> Completed
- || mycophenolate sodium / Generic mfg.
Trial completion, Enrollment change: MYCUV-IIT02: Myfortic for the Treatment of Non-infectious Intermediate Uveitis (clinicaltrials.gov) - May 9, 2017
P3, N=44, Completed, Sponsor: STZ eyetrial
No longer recruiting --> Completed Active, not recruiting --> Completed | N=144 --> 44
- | Trial initiation date, Trial primary completion date: Grading Scale of Vitreous Haze in Patients With Uveitis Using Ultrasonography (clinicaltrials.gov) - Apr 28, 2017
P=N/A, N=170, Not yet recruiting, Sponsor: University of Nebraska
Active, not recruiting --> Completed | N=144 --> 44 Initiation date: Feb 2016 --> Dec 2017 | Trial primary completion date: Feb 2017 --> Jul 2018
- | DSP-Visulex (dexamethasone sodium phosphate ophthalmic) / Aciont
Trial completion, Trial primary completion date: Safety and Efficacy Study of DSP-Visulex for the Treatment of Anterior Uveitis (clinicaltrials.gov) - Apr 27, 2017
P1/2, N=44, Completed, Sponsor: Aciont Inc
Initiation date: Feb 2016 --> Dec 2017 | Trial primary completion date: Feb 2017 --> Jul 2018 Recruiting --> Completed | Trial primary completion date: Nov 2016 --> Mar 2017
- Zinbryta (daclizumab) / Biogen, AbbVie
Trial completion: Human Anti-Tac (Daclizumab) to Treat Juvenile Idiopathic Arthritis (JIA)-Associated Uveitis (clinicaltrials.gov) - Jan 29, 2017
P2, N=6, Completed, Sponsor: National Eye Institute (NEI)
Recruiting --> Completed | Trial primary completion date: Nov 2016 --> Mar 2017 Recruiting --> Completed
- NN1213 / Novo Nordisk
Trial initiation date: Study to Treat Uveitis Associated Macular Edema (clinicaltrials.gov) - Nov 29, 2016
P2, N=15, Terminated, Sponsor: Merck Sharp & Dohme Corp.
Recruiting --> Completed Initiation date: May 2005 --> Sep 2005
- V404 / Roche
Trial primary completion date: Safety and Preliminary Efficacy Study of V404 PDS in Uveitis (clinicaltrials.gov) - Sep 26, 2016
P1/2, N=7, Terminated, Sponsor: Forsight Vision4
Initiation date: May 2005 --> Sep 2005 Trial primary completion date: Mar 2015 --> Oct 2014
- DSP-Visulex (dexamethasone sodium phosphate ophthalmic) / Aciont
Trial primary completion date: Safety and Efficacy Study of DSP-Visulex for the Treatment of Anterior Uveitis (clinicaltrials.gov) - Jul 19, 2016
P1/2, N=45, Recruiting, Sponsor: Aciont Inc
Trial primary completion date: Mar 2015 --> Oct 2014 Trial primary completion date: Dec 2015 --> Nov 2016
- || Humira (adalimumab) / AbbVie
Trial completion: ADJUVITE: Effect of Adalimumab for the Treatment of Uveitis in Juvenile Idiopathic Arthritis (clinicaltrials.gov) - Jul 1, 2016
P2/3, N=34, Completed, Sponsor: Assistance Publique - H
Trial primary completion date: Dec 2015 --> Nov 2016 Active, not recruiting --> Completed
- |||| Kevzara (sarilumab) / Asahi Kasei, Regeneron, Sanofi
Trial completion: SARILNIUSATURN: Phase II Study to Analyze Sarilumab in Non-Infectious Uveitis (clinicaltrials.gov) - May 3, 2016
P2, N=58, Completed, Sponsor: Sanofi
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Orencia (abatacept) / BMS
Enrollment closed, Enrollment change, Trial primary completion date: Abatacept in the Treatment of Uveitis (clinicaltrials.gov) - Apr 7, 2016
P2, N=10, Active, not recruiting, Sponsor: Oregon Health and Science University
Active, not recruiting --> Completed Recruiting --> Active, not recruiting | N=20 --> 10 | Trial primary completion date: Mar 2016 --> Jun 2017
- Actemra IV (tocilizumab) / Roche, JW Pharma
Trial termination: Tocilizumab in the Management of Juvenile Idiopathic Arthritis Associated Uveitis (clinicaltrials.gov) - Apr 7, 2016
P1/2, N=3, Terminated, Sponsor: Eric B. Suhler
Recruiting --> Active, not recruiting | N=20 --> 10 | Trial primary completion date: Mar 2016 --> Jun 2017 Recruiting --> Terminated; insufficient enrollment
- spironolactone / Generic mfg.
Trial completion: Effect of Spironolactone in Treating Chronic Non-resolutive Central Serous Chorioretinitis (clinicaltrials.gov) - Feb 26, 2016
P1/2, N=17, Completed, Sponsor: Institut National de la Sant
Recruiting --> Terminated; insufficient enrollment Recruiting --> Completed
- | Humira (adalimumab) / AbbVie
Trial primary completion date: ADJUVITE: Effect of Adalimumab for the Treatment of Uveitis in Juvenile Idiopathic Arthritis (clinicaltrials.gov) - Jan 17, 2016
P2/3, N=34, Active, not recruiting, Sponsor: Assistance Publique - H
Recruiting --> Completed Trial primary completion date: Nov 2015 --> Nov 2014
- ||||||| Sonsuvi (brimapitide) / Kuste Biopharma, Altamira Therap
Trial completion, Trial primary completion date, Surgery: Efficacy and Safety of XG-102 in Reduction of Post-cataract Surgery Intraocular Inflammation (clinicaltrials.gov) - Jan 11, 2016
P3, N=339, Completed, Sponsor: Xigen SA
Trial primary completion date: Nov 2015 --> Nov 2014 Active, not recruiting --> Completed | Trial primary completion date: Jul 2015 --> Dec 2015
- | piclidenoson (CF101) - Can / Fite
Trial initiation date, Trial primary completion date: Safety &Efficacy of CF101 to Subjects With Uveitis (clinicaltrials.gov) - Dec 17, 2015
P2, N=45, Not yet recruiting, Sponsor: Can-Fite BioPharma
Active, not recruiting --> Completed | Trial primary completion date: Jul 2015 --> Dec 2015 Initiation date: Sep 2015 --> Jan 2017 | Trial primary completion date: Sep 2016 --> Sep 2018
- Trial initiation date, Trial primary completion date: Grading Scale of Vitreous Haze in Patients With Uveitis Using Ultrasonography (clinicaltrials.gov) - Dec 4, 2015
P=N/A, N=170, Not yet recruiting, Sponsor: University of Nebraska
Initiation date: Sep 2015 --> Jan 2017 | Trial primary completion date: Sep 2016 --> Sep 2018 Initiation date: Jan 2015 --> Feb 2016 | Trial primary completion date: Dec 2015 --> Feb 2017
- Zirgan (ganciclovir ophthalmic gel) / Bausch Health, Thea Laboratories
Trial completion: Topical Administration of 0.15% Ganciclovir Gel for CMV Anterior Uveitis / Endotheliitis (clinicaltrials.gov) - Nov 19, 2015
P=N/A, N=29, Completed, Sponsor: Singapore National Eye Centre
Initiation date: Jan 2015 --> Feb 2016 | Trial primary completion date: Dec 2015 --> Feb 2017 Recruiting --> Completed
- | gevokizumab (VPM087) / Novartis
Trial termination: EYEGUARD (clinicaltrials.gov) - Oct 22, 2015
P3, N=281, Terminated, Sponsor: XOMA (US) LLC
Recruiting --> Completed Recruiting --> Terminated
- gevokizumab (VPM087) / Novartis
Enrollment change, Trial termination: EYEGUARD (clinicaltrials.gov) - Oct 22, 2015
P3, N=4, Terminated, Sponsor: XOMA (US) LLC
Recruiting --> Terminated N=28 --> 4 | Recruiting --> Terminated
- | gevokizumab (VPM087) / Novartis
Enrollment change, Trial termination: EYEGUARD (clinicaltrials.gov) - Oct 22, 2015
P3, N=69, Terminated, Sponsor: XOMA (US) LLC
N=28 --> 4 | Recruiting --> Terminated N=300 --> 69 | Enrolling by invitation --> Terminated
- | gevokizumab (VPM087) / Novartis
Enrollment change, Trial termination: Safety and Efficacy Study of Gevokizumab to Treat Active Non-infectious Uveitis (clinicaltrials.gov) - Oct 22, 2015
P3, N=200, Terminated, Sponsor: XOMA (US) LLC
N=300 --> 69 | Enrolling by invitation --> Terminated N=300 --> 200 | Recruiting --> Terminated
- ||||| mycophenolate sodium / Generic mfg.
Enrollment closed, Trial primary completion date: MYCUV-IIT02: Myfortic for the Treatment of Non-infectious Intermediate Uveitis (clinicaltrials.gov) - Aug 21, 2015
P3, N=144, Active, not recruiting, Sponsor: STZ eyetrial
N=300 --> 200 | Recruiting --> Terminated Recruiting --> Active, not recruiting | Trial primary completion date: Mar 2013 --> Oct 2015
- ||| Kevzara (sarilumab) / Asahi Kasei, Regeneron, Sanofi
Enrollment closed: SARILNIUSATURN: Phase II Study to Analyze Sarilumab in Non-Infectious Uveitis (clinicaltrials.gov) - Jun 9, 2015
P2, N=57, Active, not recruiting, Sponsor: Sanofi
Recruiting --> Active, not recruiting | Trial primary completion date: Mar 2013 --> Oct 2015 Recruiting --> Active, not recruiting
- cyclosporin A microemulsion / Generic mfg., everolimus / Generic mfg.
Trial completion: Everolimus for the Treatment of Uveitis Unresponsive to Cyclosporine A (clinicaltrials.gov) - May 27, 2015
P2, N=12, Completed, Sponsor: Carsten Heinz
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- | Trial completion, Enrollment change: PEMF: an Adjunct Therapy for Anterior Uveitis (clinicaltrials.gov) - May 14, 2015
P=N/A, N=19, Completed, Sponsor: Massachusetts Eye and Ear Infirmary
Active, not recruiting --> Completed Active, not recruiting --> Completed | N=24 --> 19
- ||||| Sonsuvi (brimapitide) / Kuste Biopharma, Altamira Therap
Enrollment closed, Surgery: Efficacy and Safety of XG-102 in Reduction of Post-cataract Surgery Intraocular Inflammation (clinicaltrials.gov) - Apr 25, 2015
P3, N=300, Active, not recruiting, Sponsor: Xigen SA
Active, not recruiting --> Completed | N=24 --> 19 Recruiting --> Active, not recruiting
- || Kevzara (sarilumab) / Asahi Kasei, Regeneron, Sanofi
Trial primary completion date: SARILNIUSATURN: Phase II Study to Analyze Sarilumab in Non-Infectious Uveitis (clinicaltrials.gov) - Apr 14, 2015
P2, N=57, Recruiting, Sponsor: Sanofi
Recruiting --> Active, not recruiting Trial primary completion date: Dec 2015 --> Jul 2015
- Enrollment closed: PEMF: an Adjunct Therapy for Anterior Uveitis (clinicaltrials.gov) - Mar 14, 2015
P=N/A, N=24, Active, not recruiting, Sponsor: Massachusetts Eye and Ear Infirmary
Trial primary completion date: Dec 2015 --> Jul 2015 Recruiting --> Active, not recruiting
- V404 / Roche
Enrollment change, Trial termination: Safety and Preliminary Efficacy Study of V404 PDS in Uveitis (clinicaltrials.gov) - Mar 7, 2015
P1/2, N=7, Terminated, Sponsor: Forsight Vision4
Recruiting --> Active, not recruiting N=20 --> 7 | Recruiting --> Terminated; Study terminated due to unacceptable frequency of drug related adverse events
- |||| gevokizumab (VPM087) / Novartis
Trial primary completion date: EYEGUARD (clinicaltrials.gov) - Feb 19, 2015
P3, N=300, Recruiting, Sponsor: XOMA (US) LLC
N=20 --> 7 | Recruiting --> Terminated; Study terminated due to unacceptable frequency of drug related adverse events Trial primary completion date: Dec 2014 --> Mar 2015
- |||| gevokizumab (VPM087) / Novartis
Trial primary completion date: Safety and Efficacy Study of Gevokizumab to Treat Active Non-infectious Uveitis (clinicaltrials.gov) - Feb 19, 2015
P3, N=300, Recruiting, Sponsor: XOMA (US) LLC
Trial primary completion date: Dec 2014 --> Mar 2015 Trial primary completion date: Dec 2014 --> Jun 2015
- || Kevzara (sarilumab) / Asahi Kasei, Regeneron, Sanofi
Trial primary completion date: SARILNIUSATURN: Phase II Study to Analyze Sarilumab in Non-Infectious Uveitis (clinicaltrials.gov) - Jan 9, 2015
P2, N=57, Recruiting, Sponsor: Sanofi
Trial primary completion date: Dec 2014 --> Jun 2015 Trial primary completion date: Sep 2016 --> Dec 2015
- Orencia (abatacept) / BMS
Trial primary completion date: Abatacept in the Treatment of Uveitis (clinicaltrials.gov) - Jan 9, 2015
P2, N=20, Recruiting, Sponsor: Oregon Health and Science University
Trial primary completion date: Sep 2016 --> Dec 2015 Trial primary completion date: Mar 2015 --> Mar 2016
- ||| Clinical: Grading Scale of Vitreous Haze in Patients With Uveitis Using Ultrasonography (clinicaltrials.gov) - Dec 8, 2014
P=N/A, N=170, Not yet recruiting, Sponsor: University of Nebraska
- DSP-Visulex (dexamethasone sodium phosphate ophthalmic) / Aciont
New P1/2 trial: Safety and Efficacy Study of DSP-Visulex for the Treatment of Anterior Uveitis (clinicaltrials.gov) - Dec 5, 2014
P1/2, N=45, Recruiting, Sponsor: Aciont Inc
- ||||| Cosentyx (secukinumab) / Novartis
Trial initiation date: Phase III Study in Refractory Behcet's Disease (clinicaltrials.gov) - Nov 6, 2014
P3, N=117, Completed, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Mar 2015 --> Mar 2016 Initiation date: May 2009 --> Oct 2009
- | gevokizumab (VPM087) / Novartis
Enrollment open: EYEGUARD (clinicaltrials.gov) - Nov 5, 2014
P3, N=28, Recruiting, Sponsor: XOMA (US) LLC
Initiation date: May 2009 --> Oct 2009 Not yet recruiting --> Recruiting
- || Kevzara (sarilumab) / Asahi Kasei, Regeneron, Sanofi
Trial primary completion date: SARILNIUSATURN: Phase II Study to Analyze Sarilumab in Non-Infectious Uveitis (clinicaltrials.gov) - Oct 17, 2014
P2, N=57, Recruiting, Sponsor: Sanofi
Not yet recruiting --> Recruiting Trial primary completion date: Jan 2016 --> Sep 2016